Allucent Receives BARDA-Funded Project NextGen Award to Support a COVID-19 Vaccine Decentralized Clinical Trial
Allucent Recognized with Two CRO Leadership Awards
Investments Report with Dr. Mark A. Goldberg
Allucent Awarded BARDA Contract to Support Acceleration of Next-Generation COVID-19 Booster Vaccines
Allucent Selects THREAD To Power Patient Direct Trials Offering
Allucent Launches Decentralized Clinical Trial Solution at 2023 World Orphan Drug Congress
Allucent Appoints Alexander J. MacDonald as Vice President of Model-Informed Drug Development
Allucent Appoints Life Science Veteran, Bob Millham, to Head Newly Formed Customer Engagement Unit
Allucent Appoints Lisa Benincosa as Senior Vice President of Clinical Pharmacology Strategy
Allucent Is Now Great Place To Work Certified
Allucent Appoints Alexander Berg as Vice President of Clinical Pharmacology Development and Operations
Allucent Appoints Sugato De as Vice President of Regulatory Strategy and Head of Medical Technology
Allucent Expands Presence in India and Deepens World-Class Operational Functions with Opening of New Office in Chennai
Allucent Chairman and CEO Mark A. Goldberg Honored by PharmaVoice as One of the Year’s 100 Most Inspiring People in Life Sciences
Allucent Appoints Steffany Cox as Chief Marketing Officer
Allucent Appoints President of Clinical Pharmacology, Modeling and Simulation
CATO SMS is Now Allucent
CATO SMS and Pharm-Olam Merge to Create Global Biopharmaceutical Services Leader
CATO SMS Appoints Regulatory Strategy Leader in Pharmacology and Toxicology
CATO SMS Appoints Vice President of Regulatory Strategy Cell and Gene Therapy
CATO SMS Appoints Dr. Teresa Nunes Chief Medical Officer
CATO SMS Appoints Vice President of Regulatory Strategy
CATO SMS Appoints President of Clinical Trial Operations
CATO SMS Appoints Regulatory Strategy Leader
CATO SMS Acquires Nuventra To Expand Drug Development Offering Into Clinical Pharmacology
Pharm-Olam Enrolling UK Volunteers for Phase 3 Valneva COVID-19 Vaccine Study
CATO SMS Announces Consulting Leadership Appointment
US Department of Defense selects Pharm-Olam as CRO for Adalimumab COVID Therapeutic Trial
LAVA Therapeutics signed agreement with CATO SMS to conduct its Phase I/IIa trial with T-cell engager LAVA-051 in hematologic malignancies
BARDA Selects Pharm-Olam to Support Clinical Trial Planning & Execution for up to 5 Years
Double Bond Pharmaceutical concludes Key Opinion Leader (KOL) meeting, an important milestone for SI-053 Phase 1 clinical study
Pharm-Olam Selected as a CRO for Department of Defense Support to Operation Warp Speed Vaccine Trials, Partnering with Geneva Foundation
CATO SMS Acquires Array Biostatistics
CATO SMS Unveils New Brand
Pharm-Olam Positioning for Growth Trajectory
Pharm-Olam Launches New Protocol Optimization Service
Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers
CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial
Pharm-Olam recognized by 2020 CRO Leadership Awards second year in a row
Accredited Internationally Qualified Clinical Research Auditor Standard Launches
Pharm-Olam selected to support Revive Therapeutics development of Bucillamine for COVID-19
Pharm-Olam’s Response to COVID-19: Safety, Community, Research
CATO Research Announces Merger With SMS-Oncology
Pharm-Olam names new CEO, Dr. Robert Davie
Importance of Natural History Studies to Rare Disease Drug Development
Pharm-Olam Webinar Helps Sponsors Manage Rescue Study Transitions
Cato Research Appoints Life Sciences Leader And Innovator To Executive Chairman
Pharm-Olam Wins 2019 CRO Leadership Awards
Celebrating 25-Year Anniversary and Enhanced Rare Disease Services
Pharm-Olam Enrolls Patients in Zealand Pharma Orphan Drug Study
Orphan Trial leads to First Therapeutic for the Treatment for aTTP
Pharm-Olam Unifies Data on Medidata Cloud, Eliminating Silos
Pharm-Olam Supports Clinical Trials and Sponsors Compliance with GDPR
Webinar: GDPR Implementation Across Global Clinical Trial Industry
Pharm-Olam LLC Appoints Dr. Kelly McKee as Chief Medical Officer
2017 Winner in CRO Leadership Awards for Second Consecutive Year
Pharm-Olam International Adds John Barry as Chief Operating Officer
Pharm-Olam Webinar: Evolution of Response Evaluation Oncology Trials
Pharm-Olam LLC Announces New Addition to Lead Biostatistics Team
Quad-C Management Announces Investment in Pharm-Olam LLC
Using Medidata Rave improves Data Management & Reporting Capabilities
Pharm-Olam adds New Addition to Quality and Compliance Leadership Team
Webinar: Global Clinical Research Leaders Address Rescue Study Challenges
Pharm-Olam Adds Director of Scientific Development
Pharm-Olam LLC Nominated for 2016 Scrip Awards Best Full-Service CRO
37th Telly Award Winner for Promotion of Allergy Clinical Research
Pharm-Olam Bolsters Client Outreach with Proposals and Contracts hire
Pharm-Olam International Strengthens Country Leadership with Strategic Hire in Mexico
Pharm-Olam International Adds Regional Director, Clinical Operations
Pharm-Olam International Awarded Six CRO Leadership Awards
Pharm-Olam Continues Global Expansion; Adds Full-Service Coverage in Asia-Pacific Region
Pharm-Olam Strengthens Leadership Team with New CFO
Pharm-Olam International Expands to Larger Facility in Poland
Pharm-Olam International Opens a New Office in Paris, France; Continues Global Expansion
Pharm-Olam's Case Study on Automated Sample Retention for BA/BE
Pharm-Olam: Phase III Pulmonary Arterial Hypertension study completed
Pharm-Olam releases a corporate overview video
Webinar: How political events are affecting clinical trials in Ukraine
Pharm-Olam International Celebrates 20-Year Anniversary
Pharm-Olam completes birch and grass pollen allergy studies
Pharm-Olam Expands into IsraelPharm-Olam is pleased to announce expansion into Israel. Incorporating Israel into your clinical trials offers you several benefits including:
Pharm-Olam expands Clinical Trial Services to Kazakhstan